

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Jun 2026

### Evaluating the effects of vitamin D on CGRP levels, inflammatory markers, Treg/Th17 balance and episodic migraine characteristics in Adult migraineurs

#### Protocol summary

##### Study aim

To determine the effects of vitamin D compared to placebo on CGRP levels, inflammatory markers, Treg/Th17 balance and episodic migraine characteristics in Adults migraine

##### Design

The present study will be conducted as a 16-week phase 1 randomized double-blind placebo-controlled trial on 80 episodic migraineurs allocated in 2 parallel groups each consisted of 40 episodic migraine patients who will receive vitamin D or placebo. From the beginning of the study, A and B codes are available to researchers to recruit the patients using twenty 4-Block Randomizations.

##### Settings and conduct

The study will perform at the tertiary headache clinic of Sina University Hospital. Information on demographic data and headache characteristics will be collected. A blood sample will be taken at 8 cc. Patients will be randomized to either the intervention or placebo group at the beginning of the fifth week for 12 weeks.

##### Participants/Inclusion and exclusion criteria

episodic migraine patients according to ICHDIII criteria aged 18 to 45 years

##### Intervention groups

Patients in the intervention group will receive 1 capsule containing 2,000 IU of vitamin D per day in addition to routine medications prescribed by our study neurologist. While the placebo group will receive 1 placebo capsule which will be indistinguishable from vitamin D capsules in taste and appearance. Patients will be asked to not change their medications during the study.

##### Main outcome variables

headache attack frequency per month; headache severity (VAS); attack duration (min per month)

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20151128025267N6**

Registration date: **2018-07-11, 1397/04/20**

Registration timing: **registered\_while\_recruiting**

Last update: **2018-07-11, 1397/04/20**

Update count: **0**

##### Registration date

2018-07-11, 1397/04/20

##### Registrant information

##### Name

Maryam Mahmoudi

##### Name of organization / entity

School of Nutritional Sciences & Dietetics, Tehran University of Medical Sciences,

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8895 5975

##### Email address

m-mahmoudi@sina.tums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-06-22, 1397/04/01

##### Expected recruitment end date

2020-02-20, 1398/12/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

**Trial completion date**

empty

**Scientific title**

Evaluating the effects of vitamin D on CGRP levels, inflammatory markers, Treg/Th17 balance and episodic migraine characteristics in Adult migraineurs

**Public title**

Evaluating the effects of vitamin D on migraine headache and its possible associated factors

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

having BMI between 18.5-30 kg/m<sup>2</sup> Migraine diagnosis according to The International Classification of Headache Disorders 3rd edition having 3-15 migraine headache attacks in last 3 months suffering from migraine for at least 6 months prior to study

**Exclusion criteria:**

unwillingness to participate in the study daily consumption of NSAIDs in 3 months prior to study taking vitamin D supplements in 3 months prior to study taking magnesium, calcium, zinc, vitamin B groups and vitamin C supplements during the study period taking anti-epileptic drugs such as topiramate, sodium valproate and carbamazepine taking thiazide diuretics, Glucocorticoid, statins and orlistat taking anti-psychotic drugs menopause pregnancy and lactation suffering from gastrointestinal disorders (IBD, IBS,...), liver and kidney disorders, cancer, Sarcoidosis, rickets, and osteomalacia based on physician diagnosis and/or past medical history

**Age**

From **18 years** old to **45 years** old

**Gender**

Both

**Phase**

0

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**

Target sample size: **80**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

according to double-blind nature of this trial, from the beginning of the study, A and B codes are available to researchers to recruit the patients using twenty 4-Block Randomization.

**Blinding (investigator's opinion)**

Double blinded

**Blinding description**

Only one of the staff of the headache department is aware of the type of assigned intervention for each patient (vitamin D or placebo, which are marked by A or B codes). Finally, after collecting the data, she unseals

the codes for researchers, the statistical analyst, and those who prepare the manuscript.

**Placebo**

Used

**Assignment**

Parallel

**Other design features**

The duration of this randomized, double-blind, placebo controlled trial will be 16 weeks, consisting of 4-week of baseline following by 12-week intervention. Also, patients will be instructed to fill out a headache diary designed by our headache specialist neurologist in order to provide headache characteristics including headache severity, duration of attacks, number of attacks, and number of days with headache in the month. Patients will be asked to not change their medications during the study.

**Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Tehran University of Medical Sciences

**Street address**

Ghods Street

**City**

Tehran

**Province**

Tehran

**Postal code**

1417653761

**Approval date**

2018-04-08, 1397/01/19

**Ethics committee reference number**

IR.TUMS.VCR.REC.1397.094

**Health conditions studied****1****Description of health condition studied**

migraine headache

**ICD-10 code**

G43

**ICD-10 code description**

Migraine

**Primary outcomes****1****Description**

migraine attack frequency per month

**Timepoint**

baseline-end of study

**Method of measurement**

headache diary

## 2

### **Description**

attack severity

### **Timepoint**

baseline-end of study

### **Method of measurement**

headache diary-visual analogue scale

## 3

### **Description**

headache attack duration (min per month)

### **Timepoint**

baseline-end of study

### **Method of measurement**

headache diary-visual analogue scale

## **Secondary outcomes**

## 1

### **Description**

serum 25 (OH) D3

### **Timepoint**

baseline- end of study

### **Method of measurement**

laboratory test

## 2

### **Description**

serum vitamin D receptor

### **Timepoint**

baseline- end of study

### **Method of measurement**

laboratory test

## 3

### **Description**

determining inflammatory status (including serum levels of iNOS, IL 6, Cox 2, CGRP, and IL10 )

### **Timepoint**

baseline- end of study

### **Method of measurement**

laboratory test

## 4

### **Description**

Determining Treg/th17 balance (including serum levels of TGF b and IL-17)

### **Timepoint**

baseline- end of study

### **Method of measurement**

laboratory test

## 5

### **Description**

serum prolactin levels

### **Timepoint**

baseline- end of study

### **Method of measurement**

laboratory test

## **Intervention groups**

## 1

### **Description**

Intervention group: intervention group will receive 1 capsule which contains 2000 of vitamin D every day for 12 weeks

### **Category**

Prevention

## 2

### **Description**

Control group: placebo group will receive 1 capsule of placebo with the same smell and taste as vitamin D during 12-week period.

### **Category**

Prevention

## **Recruitment centers**

## 1

### **Recruitment center**

#### **Name of recruitment center**

Sina University Hospital

#### **Full name of responsible person**

Dr Mansoureh Togha

#### **Street address**

Imam Khomeini Street

#### **City**

Tehran

#### **Province**

Tehran

#### **Postal code**

1136746911

#### **Phone**

+98 21 6312 1506

#### **Email**

toghae@sina.tums.ac.ir

## **Sponsors / Funding sources**

## 1

### **Sponsor**

#### **Name of organization / entity**

Tehran University of Medical Sciences

#### **Full name of responsible person**

Ms Fatemeh Javadi

#### **Street address**

Shahid Naderi Street

#### **City**

Tehran

#### **Province**

Tehran  
**Postal code**  
14155-6117  
**Phone**  
+98 21 8895 5975  
**Email**  
javadi\_fateme@yahoo.com  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Tehran University of Medical Sciences  
**Proportion provided by this source**  
60  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## **2**

### **Sponsor**

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Ms Bahare Pourghaz  
**Street address**  
Dr Gharib Street  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1419733141  
**Phone**  
+98 21 6690 3066  
**Email**  
pourghaz.bahar@gmail.com  
**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes  
**Title of funding source**  
Tehran University of Medical Sciences  
**Proportion provided by this source**  
40  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## **Person responsible for general inquiries**

### **Contact**

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Dr Maryam Mahmoudi  
**Position**  
Associate Professor  
**Latest degree**  
Ph.D.  
**Other areas of specialty/work**  
Nutrition  
**Street address**  
No: 44 Hojjat-dost Alley, Naderi St., Keshavarz Blvd,  
Tehran, Iran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
14155-6117  
**Phone**  
+98 21 8895 5975  
**Fax**  
+98 21 8895 5975  
**Email**  
m-mahmoudi@sina.tums.ac.ir

## **Person responsible for scientific inquiries**

### **Contact**

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Zeinab Ghorbani  
**Position**  
PhD candidate in Nutritional sciences  
**Latest degree**  
Master  
**Other areas of specialty/work**  
Nutrition  
**Street address**  
Shahid Naderi Street  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
14155-6117  
**Phone**  
+98 21 8895 5975  
**Email**  
zghorbani@razi.tums.ac.ir

## **Person responsible for updating data**

### **Contact**

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**

Zeinab Ghorbani

**Position**

PhD candidate in Nutritional sciences

**Latest degree**

Master

**Other areas of specialty/work**

Nutrition

**Street address**

Shahid Naderi Street

**City**

Tehran

**Province**

Tehran

**Postal code**

14155-6117

**Phone**

+98 21 8895 5975

**Email**

zghorbani@razi.tums.ac.ir

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available